Phase I trial of ALKS 8700 to treat multiple sclerosis begin
Posted: Mon Jul 21, 2014 2:22 am
Phase I trial of ALKS 8700 to treat multiple sclerosis begins
Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS).
The trial will assess the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy volunteers......... Read More - http://www.ms-uk.org/emergingtherapies
Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS).
The trial will assess the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy volunteers......... Read More - http://www.ms-uk.org/emergingtherapies